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each) in which they would be interested in conducting re-
search projects. Other diseases in which a high interest
level was demonstrated include asthma (85.4%), hyper-
cholesterolemia (83.3%), and arthritis (81.2%). An inter-
mediate level of interest was demonstrated with COPD
(77%), allergic rhinitis (77%), child health issues (77%),
and peptic ulcer disease (72.9%). Diseases in which a low
interest level was expressed include AIDSIHIV (18.8%),
epilepsy (12.5%), and thyroid disorders (12.5%). Addi-
tionally, 10.4% of pharmacists expressed low interest
levels in conducting studies in patients with arrhythmias,
congestive heart failure, depression, and anxiety.
CONCLUSION: Community pharmacists in this re-
search network are most interested in conducting out-
comes-related research projects in patients with common,
expensive, chronic diseases.
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Medication use is under-investigated in the 50 and older
population.
OBJECTIVE: We used data from the 1995 National Am-
bulatory Medical Care Survey (NAMCS) to evaluate pre-
scription medication use in older Americans.
METHODS: NAMCS is a nationally representative sam-
ple of ambulatory care visits in the United States and con-
tains clinical information concerning each visit, including
medication. Non-prescription products and medications
typically administered during a physician office visit or
hospitalization were excluded from analysis; all other
medications were considered prescription medications
and eligible for evaluation. We evaluated patients 50
years or older (n = 16,289 visits) and report prescription
use by age group and therapeutic and drug class. Analysis
is based on NAMCS weighted data.
RESULTS: 61 % of patient visits included renewal or pre-
scription of at least one medication. Prescription medication
use ranged from x = 1.27 prescription medications in pa-
tients aged 50-64 to x = 1.58 in patients over 85. Most
commonly prescribed therapeutic classes were cardiovascu-
lar, pain/anti-inflammatory, anti-microbial, central nervous
system, and hormone agents. Most commonly prescribed
drug classes were non-narcotic analgesics, calcium channel
blockers (CCB), diuretics, and angiotensin converting en-
zyme (ACE) inhibitors. We observed greater use of CCB
than beta blockers and diuretics in patients younger than 75
and a significant decrease in estrogen/progestin and antide-
pressant medication use in older patients.
CONCLUSION: We report a cross-sectional evaluation
of medication use in the US population 50 and older. Our
findings indicate prescribing patterns inconsistent with
national guidelines (JNC-V). Given the benefits of estro-
73
gen replacement therapy and high prevalence of depres-
sion in the elderly, decreased medication use may suggest
underprescription. Active intervention may be needed to
improve the pharmacological treatment of older patients.
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CHRONIC CARE COSTS OF NEW MEDICARE




Cost-effective care for chronic conditions is a growing
concern of health plans enrolling increasing numbers of
the elderly and disabled under Medicare risk contracts.
This study provides evidence of the prevalence, patterns
of care, and costs of chronic illnesses among new Medi-
care HMO enrollees. The results provide a foundation
for estimates of the cost-effectiveness of drug therapy and
care management programs that serve this group.
METHODS: We used national Medicare claims data to
examine chronic care services and associated costs for a
sample of 19,084 beneficiaries who enrolled in an HMO
in 1995. We constructed three measures of cost: the total
Medicare-covered cost, the cost of medical claims with
the chronic condition coded as a diagnosis, and the re-
gression-estimated effect of the chronic condition on cost.
RESULTS: 58% of the new Medicare HMO enrollees in
our sample were treated for at least one of the selected
chronic conditions in the six months before enrollment.
One-third of the new enrollees had multiple conditions
represented by diagnoses in more than one of eighteen
chronic-condition groups. Persons with chronic condi-
tions accounted for 93% of pre-enrollment Medicare
costs among new HMO enrollees. Per 1,000 enrollees,
pre-enrollment Medicare costs were greatest for those
with hypertensive disease, coronary heart disease, heart
failure, and diabetes.
CONCLUSIONS: The concentration of utilization and
costs in those with chronic conditions suggests that ap-
propriate drug therapy and care management for those
with chronic conditions should be a top priority for
HMOs with Medicare risk contracts. These estimates of
prevalence suggest a need for HMOs to screen new Medi-
care HMO enrollees for chronic conditions immediately
upon enrollment to ensure continuity of care.
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OBJECTIVE: To ascertain the existence and quality of
evidence of the value of medicines in the UK, a case study
approach was adopted.
METHODS: Four disease areas that feature in the UK
